

ABBREVIATIONS

AE Adverse event	HTPN HIV Prevention Trials Network	PBMC Peripheral blood mononuclear cell
AI Active ingredient	IAS International AIDS Society	PBPK Physiologically based pharmacokinetic
ALC Absolute lymphocyte count	1HP 1-month TB preventive	PD Pharmacodynamics
ANDA Abbreviated new drug application	IM Intramuscular	PDUFA Prescription Drug User Fee Act
API Active pharmaceutical ingredient	IND Investigational new drug	PEG Polyethylene glycol
ARCH-LA Antiretroviral concentrated + highly durable LA	INH Isoniazid	PEPFAR President's Emergency Plan for AIDS Relief
ART Antiretroviral therapy	INSTI Integrase strand transfer inhibitor	PI Protease inhibitor
ARV Antiretroviral	IP Intellectual property	PK Pharmacokinetics
AUC Area under the curve	IPT Isoniazid prevention treatment	PLWH People living with HIV
BDQ Bedaquiline	IQR Interquartile range	PoC Proof of concept
BE Bioequivalence	IR Immediate release	PrEP Pre-exposure prophylaxis
BIC bictegravir	ISFI In situ forming implant	PSG Product-specific guidance
bNAb broadly neutralizing antibody	ISL Islatrovir	PY Person-year
CAB Cabotegravir	ISR Injection site reaction	QD Once-daily
CD4 CD4 ⁺ T lymphocytes	IV Intravenous	QTc Corrected QT interval
CDMO Contract development + manufacturing organization	LA Long-acting	QW Once-weekly
CELT Centre of Excellence for Long-acting Therapeutics	LAI Long-acting injectable	RCT Randomized controlled trial
CHAI Clinton Health Access Initiative	LAPaL Long-acting therapeutics, patents, and licenses	RIF Rifampicin
CMax Maximum concentration	LEAP Long-acting extended release antiretroviral research program	RPV Rilpivirine
CMO Contract manufacturing organization	LEN Lenacapavir	RR-TB Rifampicin-resistant TB
CSA Clinical study agreement	LMIC Low-middle income country	RTV Ritonavir
DcNP Drug combination nanoparticles	LMNC Lymphomononuclear cell	SC Subcutaneous
DDI Drug-drug interaction	LN Lymph node	SHIV Simian HIV
DMPA Depo-Provera	LPV Lopinavir	SUD Substance use disorder
DOT Doravirine	LTBI Latent tuberculosis infection	SVR Sustained virologic response
DPV Dapivirine	LTZ Letrozole	TAP Target access profile
DSD Differentiated service delivery	M2 BDQ primary active metabolite	TAB Teropavimab
DTG Dolutegravir	mAbs Monoclonal antibodies	TB Tuberculosis
EFV Efavirenz	MD Multiple dose	TDF Tenofovir
EMA or EMEA European medicines agency	MDR-TB TB resistant to RIF + INH	TLC-ART Targeted long-acting and combination antiretroviral therapy
ER Extended release	MHRA Medicines and Healthcare products Regulatory Agency	TLD Tenofovir, lamivudine, dolutegravir
EU European Union	MPP Medicines Patent Pool	TLE Tenofovir, lamivudine, efavirenz
FDA Food and Drug Administration	MPT Multipurpose prevention technology	TP Triphosphate
FDC Fixed-dose combination	MSM Men who have sex with men	TPP Target product profile
F/TAF Emtricitabine/tenofovir alafenamide	NDA New drug application	TRP Target regimen profile
FTC Emtricitabine	NCD Non-communicable disease	U=U Undetectable = untransmittable
GLP Good laboratory practice	NGO Non-governmental organization	ULAI Ultra-long acting
GMP Good manufacturing practice	NHP Non-human primate	VAS Visual analog scale
G/P Glecaprevir/pibrentasvir	NIH National Institutes of Health	VL Viral load
HALo Hub for Advanced LA Therapeutics	NRTI Nucleoside reverse transcriptase translocation inhibitor	VS Virologically suppressed
HIV Human immunodeficiency virus	NTP National treatment program	WHO World Health Organization
	NVP Nevirapine	3TC Lamivudine
	PA-IC90 Protein-adjusted inhibitory concentration 90%	ZAB Zinlirvimab